Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer.
Che-Hsing LiJiunn-Liang KoYu-Ping HsiaoMing-Hung TsaiYen-Chein LaiI-Lun HsinYu-Ting KangGwo-Tarng SheuWea-Lung LinMing-Fang WuPublished in: Cancer management and research (2021)
Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a non-invasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.
Keyphrases
- advanced non small cell lung cancer
- small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- prognostic factors
- high grade
- tyrosine kinase
- climate change
- patient reported outcomes
- bone marrow
- mesenchymal stem cells
- replacement therapy
- smoking cessation